Aquinox Pharmaceuticals, the developer of small molecule therapeutics for the treatment of inflammatory disease, has closed an $18 million Series C round of financing. The round was led by Johnson & Johnson Development and included participation from new investor Augment Investment and existing investors Pfizer Venture Investments, Ventures West Capital and Baker Brothers Investments. Based in Richmond, Canada, Aquinox will use the financing to build on the success of its two recently completed Phase IIa clinical studies.
